Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-09-25

AUTHORS

Laura H. Jacobson, S. Renee Commerford, Sarah P. Gerber, Yu Alice Chen, Beatriz Dardik, Frederique Chaperon, Chad Schwartzkopf, Van Nguyen-Tran, Thomas Hollenbeck, Peter McNamara, Xiaohui He, Hong Liu, H. Martin Seidel, Anne-Liese Jaton, Jesper Gromada, Sandra Teixeira

ABSTRACT

Pharmacologic antagonism of cannabinoid 1 receptors (CB1 receptors) in the central nervous system (CNS) suppresses food intake, promotes weight loss, and improves the metabolic profile. Since the CB1 receptor is expressed both in the CNS and in peripheral tissues, therapeutic value may be gained with CB1 receptor inverse agonists acting on receptors in both domains. The present report examines the metabolic and CNS actions of a novel CB1 receptor inverse agonist, compound 64, a 1,5,6-trisubstituted pyrazolopyrimidinone. Compound 64 showed similar or superior binding affinity, in vitro potency, and pharmacokinetic profile compared to rimonabant. Both compounds improved the metabolic profile in diet-induced obese (DIO) rats and obese cynomolgus monkeys. Weight loss tended to be greater in compound 64-treated DIO rats compared to pair-fed counterparts, suggesting that compound 64 may have metabolic effects beyond those elicited by weight loss alone. In the CNS, reversal of agonist-induced hypothermia and hypolocomotion indicated that compound 64 possessed an antagonist activity in vivo. Dosed alone, compound 64 suppressed extinction of conditioned freezing (10 mg/kg) and rapid eye movement (REM) sleep (30 mg/kg), consistent with previous reports for rimonabant, although for REM sleep, compound 64 was greater than threefold less potent than for metabolic effects. Together, these data suggested that (1) impairment of extinction learning and REM sleep suppression are classic, centrally mediated responses to CB1 receptor inverse agonists, and (2) some separation may be achievable between central and peripheral effects with brain-penetrating CB1 receptor inverse agonists while maintaining metabolic efficacy. Furthermore, chronic treatment with compound 64 contributes to evidence that peripheral CB1 receptor blockade may yield beneficial outcomes that exceed those elicited by weight loss alone. More... »

PAGES

565-581

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00210-011-0686-y

DOI

http://dx.doi.org/10.1007/s00210-011-0686-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1001533608

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21947251


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Inverse Agonism", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Extinction, Psychological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Macaca fascicularis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice, Inbred C57BL", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Motor Activity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Obesity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidinones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rats, Sprague-Dawley", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, Cannabinoid, CB1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rimonabant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sleep, REM", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Distribution", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Neuroscience Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Neuroscience Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jacobson", 
        "givenName": "Laura H.", 
        "id": "sg:person.01210642561.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210642561.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Commerford", 
        "givenName": "S. Renee", 
        "id": "sg:person.01237227655.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237227655.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gerber", 
        "givenName": "Sarah P.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418185.1", 
          "name": [
            "Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Yu Alice", 
        "id": "sg:person.01034226026.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034226026.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dardik", 
        "givenName": "Beatriz", 
        "id": "sg:person.01104030755.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104030755.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neuroscience Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Neuroscience Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chaperon", 
        "givenName": "Frederique", 
        "id": "sg:person.01011172531.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011172531.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartzkopf", 
        "givenName": "Chad", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418185.1", 
          "name": [
            "Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nguyen-Tran", 
        "givenName": "Van", 
        "id": "sg:person.015453371301.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015453371301.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418185.1", 
          "name": [
            "Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hollenbeck", 
        "givenName": "Thomas", 
        "id": "sg:person.01347610057.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347610057.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418185.1", 
          "name": [
            "Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McNamara", 
        "givenName": "Peter", 
        "id": "sg:person.01150201134.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150201134.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418185.1", 
          "name": [
            "Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "He", 
        "givenName": "Xiaohui", 
        "id": "sg:person.0770431725.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770431725.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418185.1", 
          "name": [
            "Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Hong", 
        "id": "sg:person.01150042175.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150042175.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418185.1", 
          "name": [
            "Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Seidel", 
        "givenName": "H. Martin", 
        "id": "sg:person.01106253755.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106253755.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neuroscience Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Neuroscience Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jaton", 
        "givenName": "Anne-Liese", 
        "id": "sg:person.01040067126.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040067126.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gromada", 
        "givenName": "Jesper", 
        "id": "sg:person.01164252563.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164252563.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Teixeira", 
        "givenName": "Sandra", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrn2092", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012251851", 
          "https://doi.org/10.1038/nrn2092"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/346561a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034682253", 
          "https://doi.org/10.1038/346561a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ijo.2010.38", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053597823", 
          "https://doi.org/10.1038/ijo.2010.38"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature00839", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010507937", 
          "https://doi.org/10.1038/nature00839"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ijo.2010.21", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018368508", 
          "https://doi.org/10.1038/ijo.2010.21"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nn.2494", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037682590", 
          "https://doi.org/10.1038/nn.2494"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/365061a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020160837", 
          "https://doi.org/10.1038/365061a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00213-006-0650-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045515263", 
          "https://doi.org/10.1007/s00213-006-0650-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-09-25", 
    "datePublishedReg": "2011-09-25", 
    "description": "Pharmacologic antagonism of cannabinoid 1 receptors (CB1 receptors) in the central nervous system (CNS) suppresses food intake, promotes weight loss, and improves the metabolic profile. Since the CB1 receptor is expressed both in the CNS and in peripheral tissues, therapeutic value may be gained with CB1 receptor inverse agonists acting on receptors in both domains. The present report examines the metabolic and CNS actions of a novel CB1 receptor inverse agonist, compound 64, a 1,5,6-trisubstituted pyrazolopyrimidinone. Compound 64 showed similar or superior binding affinity, in vitro potency, and pharmacokinetic profile compared to rimonabant. Both compounds improved the metabolic profile in diet-induced obese (DIO) rats and obese cynomolgus monkeys. Weight loss tended to be greater in compound 64-treated DIO rats compared to pair-fed counterparts, suggesting that compound 64 may have metabolic effects beyond those elicited by weight loss alone. In the CNS, reversal of agonist-induced hypothermia and hypolocomotion indicated that compound 64 possessed an antagonist activity in vivo. Dosed alone, compound 64 suppressed extinction of conditioned freezing (10\u00a0mg/kg) and rapid eye movement (REM) sleep (30\u00a0mg/kg), consistent with previous reports for rimonabant, although for REM sleep, compound 64 was greater than threefold less potent than for metabolic effects. Together, these data suggested that (1) impairment of extinction learning and REM sleep suppression are classic, centrally mediated responses to CB1 receptor inverse agonists, and (2) some separation may be achievable between central and peripheral effects with brain-penetrating CB1 receptor inverse agonists while maintaining metabolic efficacy. Furthermore, chronic treatment with compound 64 contributes to evidence that peripheral CB1 receptor blockade may yield beneficial outcomes that exceed those elicited by weight loss alone.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00210-011-0686-y", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1015404", 
        "issn": [
          "0028-1298", 
          "1432-1912"
        ], 
        "name": "Naunyn-Schmiedeberg's Archives of Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "384"
      }
    ], 
    "keywords": [
      "CB1 receptor inverse agonist", 
      "receptor inverse agonist", 
      "central nervous system", 
      "inverse agonists", 
      "compound 64", 
      "weight loss", 
      "metabolic profile", 
      "metabolic effects", 
      "peripheral CB1 receptor blockade", 
      "diet-induced obese rats", 
      "diet-induced obese model", 
      "rapid eye movement (REM) sleep", 
      "obese cynomolgus monkeys", 
      "REM sleep suppression", 
      "CB1 receptor blockade", 
      "agonist-induced hypothermia", 
      "eye movement sleep", 
      "cannabinoid 1 receptor", 
      "pair-fed counterparts", 
      "receptor blockade", 
      "pharmacologic antagonism", 
      "CNS actions", 
      "DIO rats", 
      "chronic treatment", 
      "sleep suppression", 
      "peripheral effects", 
      "metabolic efficacy", 
      "movement sleep", 
      "CB1 receptors", 
      "obese rats", 
      "peripheral tissues", 
      "food intake", 
      "cynomolgus monkeys", 
      "REM sleep", 
      "obese model", 
      "pharmacokinetic profile", 
      "nervous system", 
      "therapeutic value", 
      "agonists", 
      "antagonist activity", 
      "receptors", 
      "extinction learning", 
      "present report", 
      "rats", 
      "previous reports", 
      "sleep", 
      "beneficial outcomes", 
      "report", 
      "hypolocomotion", 
      "central activity", 
      "hypothermia", 
      "blockade", 
      "intake", 
      "impairment", 
      "efficacy", 
      "loss", 
      "monkeys", 
      "outcomes", 
      "treatment", 
      "Dosed", 
      "antagonism", 
      "activity", 
      "effect", 
      "vivo", 
      "profile", 
      "tissue", 
      "potency", 
      "suppression", 
      "response", 
      "evidence", 
      "contributes", 
      "action", 
      "pyrazolopyrimidinones", 
      "reversal", 
      "affinity", 
      "data", 
      "compounds", 
      "counterparts", 
      "aspects", 
      "values", 
      "freezing", 
      "model", 
      "novel", 
      "characterization", 
      "system", 
      "domain", 
      "learning", 
      "extinction", 
      "separation", 
      "novel CB1 receptor inverse agonist", 
      "brain-penetrating CB1 receptor inverse agonists", 
      "compound 64 contributes"
    ], 
    "name": "Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity", 
    "pagination": "565-581", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1001533608"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00210-011-0686-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21947251"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00210-011-0686-y", 
      "https://app.dimensions.ai/details/publication/pub.1001533608"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_550.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00210-011-0686-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00210-011-0686-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00210-011-0686-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00210-011-0686-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00210-011-0686-y'


 

This table displays all metadata directly associated to this object as RDF triples.

374 TRIPLES      22 PREDICATES      146 URIs      130 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00210-011-0686-y schema:about N02058abba8414ee1abffd516a570ce55
2 N239330703236426e9bdb182f7d038ee4
3 N3b48cbc42fa24bc48fe30379e6e4dc65
4 N43023a6c6852469eb54ce216b09ac06a
5 N4aaf148c8086472885c6601d4d35444c
6 N4c5e3a571dba42d7ae367b6f1413fa23
7 N69097830af9646bdbf3f5a8e265a5ec2
8 N7047b2e22e394c05ab6350bce4750b57
9 N7d33e8d9b61d4bb980744584c83b4277
10 N89407d1f046c4ed8aaa59faffc37fb7c
11 N8bbafa29c2144a4a9eb195243d99c6d2
12 N967c57a3072c411ca69dee4d23029102
13 N9c55bfb2248b4d5d95ce4d6371cafa6a
14 Na7e4932a828f422491a02b1cb0b5c214
15 Nbd9e45b790a74632b6542cd410915589
16 Nc246610ca41e488ba149a37e01b2b1f2
17 Nc6bac8bdf178479e8350835b0384bb43
18 Ned75cda1ccdb467e85b5bfc20a52e6ec
19 Nf18cc33b6bf148f8a2f849506cf55e80
20 Nf9981d2d2b5145c5b1ef52f82cad2848
21 anzsrc-for:11
22 anzsrc-for:1109
23 schema:author Nd0be0a18d7b44502b20e0bca67092203
24 schema:citation sg:pub.10.1007/s00213-006-0650-6
25 sg:pub.10.1038/346561a0
26 sg:pub.10.1038/365061a0
27 sg:pub.10.1038/ijo.2010.21
28 sg:pub.10.1038/ijo.2010.38
29 sg:pub.10.1038/nature00839
30 sg:pub.10.1038/nn.2494
31 sg:pub.10.1038/nrn2092
32 schema:datePublished 2011-09-25
33 schema:datePublishedReg 2011-09-25
34 schema:description Pharmacologic antagonism of cannabinoid 1 receptors (CB1 receptors) in the central nervous system (CNS) suppresses food intake, promotes weight loss, and improves the metabolic profile. Since the CB1 receptor is expressed both in the CNS and in peripheral tissues, therapeutic value may be gained with CB1 receptor inverse agonists acting on receptors in both domains. The present report examines the metabolic and CNS actions of a novel CB1 receptor inverse agonist, compound 64, a 1,5,6-trisubstituted pyrazolopyrimidinone. Compound 64 showed similar or superior binding affinity, in vitro potency, and pharmacokinetic profile compared to rimonabant. Both compounds improved the metabolic profile in diet-induced obese (DIO) rats and obese cynomolgus monkeys. Weight loss tended to be greater in compound 64-treated DIO rats compared to pair-fed counterparts, suggesting that compound 64 may have metabolic effects beyond those elicited by weight loss alone. In the CNS, reversal of agonist-induced hypothermia and hypolocomotion indicated that compound 64 possessed an antagonist activity in vivo. Dosed alone, compound 64 suppressed extinction of conditioned freezing (10 mg/kg) and rapid eye movement (REM) sleep (30 mg/kg), consistent with previous reports for rimonabant, although for REM sleep, compound 64 was greater than threefold less potent than for metabolic effects. Together, these data suggested that (1) impairment of extinction learning and REM sleep suppression are classic, centrally mediated responses to CB1 receptor inverse agonists, and (2) some separation may be achievable between central and peripheral effects with brain-penetrating CB1 receptor inverse agonists while maintaining metabolic efficacy. Furthermore, chronic treatment with compound 64 contributes to evidence that peripheral CB1 receptor blockade may yield beneficial outcomes that exceed those elicited by weight loss alone.
35 schema:genre article
36 schema:inLanguage en
37 schema:isAccessibleForFree false
38 schema:isPartOf Nd25f405aa38b462e85244999ed754f12
39 Nd8c824e90df941519572d4dfd6ca98a0
40 sg:journal.1015404
41 schema:keywords CB1 receptor blockade
42 CB1 receptor inverse agonist
43 CB1 receptors
44 CNS actions
45 DIO rats
46 Dosed
47 REM sleep
48 REM sleep suppression
49 action
50 activity
51 affinity
52 agonist-induced hypothermia
53 agonists
54 antagonism
55 antagonist activity
56 aspects
57 beneficial outcomes
58 blockade
59 brain-penetrating CB1 receptor inverse agonists
60 cannabinoid 1 receptor
61 central activity
62 central nervous system
63 characterization
64 chronic treatment
65 compound 64
66 compound 64 contributes
67 compounds
68 contributes
69 counterparts
70 cynomolgus monkeys
71 data
72 diet-induced obese model
73 diet-induced obese rats
74 domain
75 effect
76 efficacy
77 evidence
78 extinction
79 extinction learning
80 eye movement sleep
81 food intake
82 freezing
83 hypolocomotion
84 hypothermia
85 impairment
86 intake
87 inverse agonists
88 learning
89 loss
90 metabolic effects
91 metabolic efficacy
92 metabolic profile
93 model
94 monkeys
95 movement sleep
96 nervous system
97 novel
98 novel CB1 receptor inverse agonist
99 obese cynomolgus monkeys
100 obese model
101 obese rats
102 outcomes
103 pair-fed counterparts
104 peripheral CB1 receptor blockade
105 peripheral effects
106 peripheral tissues
107 pharmacokinetic profile
108 pharmacologic antagonism
109 potency
110 present report
111 previous reports
112 profile
113 pyrazolopyrimidinones
114 rapid eye movement (REM) sleep
115 rats
116 receptor blockade
117 receptor inverse agonist
118 receptors
119 report
120 response
121 reversal
122 separation
123 sleep
124 sleep suppression
125 suppression
126 system
127 therapeutic value
128 tissue
129 treatment
130 values
131 vivo
132 weight loss
133 schema:name Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity
134 schema:pagination 565-581
135 schema:productId N4e6d5f0db4f2427ebdd34678efe4e28b
136 Nb8e7fe5242894e338585954f973b803e
137 Ne8892cb4659b49f9bea8eb7b3dab145e
138 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001533608
139 https://doi.org/10.1007/s00210-011-0686-y
140 schema:sdDatePublished 2021-11-01T18:16
141 schema:sdLicense https://scigraph.springernature.com/explorer/license/
142 schema:sdPublisher Na2ce251b4a424d50913c18835d5100ca
143 schema:url https://doi.org/10.1007/s00210-011-0686-y
144 sgo:license sg:explorer/license/
145 sgo:sdDataset articles
146 rdf:type schema:ScholarlyArticle
147 N02058abba8414ee1abffd516a570ce55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Male
149 rdf:type schema:DefinedTerm
150 N063f036eb6fb4f7cbcf6714be846133a rdf:first N0754fcb16f5542a9971e8804e3a0dd25
151 rdf:rest Nd12df7cdedb446579afe6c6559132090
152 N0754fcb16f5542a9971e8804e3a0dd25 schema:affiliation grid-institutes:grid.418424.f
153 schema:familyName Schwartzkopf
154 schema:givenName Chad
155 rdf:type schema:Person
156 N126c42cd209841489df2471273f92530 rdf:first sg:person.01104030755.00
157 rdf:rest N8732554db88d45d4852dd9325ec9a60b
158 N239330703236426e9bdb182f7d038ee4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Extinction, Psychological
160 rdf:type schema:DefinedTerm
161 N2ee444b4abaa4e11b7a02f7984a61f2e rdf:first sg:person.0770431725.37
162 rdf:rest Na705470780a04f73900b02d9cfb093cd
163 N30624a82136e479daeb693bdc4fddd43 rdf:first sg:person.01347610057.60
164 rdf:rest N82f3b2c6963f408bad7c1104f14c8a31
165 N324a13b7b35d4c2abe306b7b0aaaf86c rdf:first N6c94e147e9a14c909478ae9dde75a0c3
166 rdf:rest Nb385d21b18ee481db7cfcd249c4d75e1
167 N3b48cbc42fa24bc48fe30379e6e4dc65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Dose-Response Relationship, Drug
169 rdf:type schema:DefinedTerm
170 N43023a6c6852469eb54ce216b09ac06a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Rats, Sprague-Dawley
172 rdf:type schema:DefinedTerm
173 N4aaf148c8086472885c6601d4d35444c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Tissue Distribution
175 rdf:type schema:DefinedTerm
176 N4c5e3a571dba42d7ae367b6f1413fa23 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Mice
178 rdf:type schema:DefinedTerm
179 N4e6d5f0db4f2427ebdd34678efe4e28b schema:name pubmed_id
180 schema:value 21947251
181 rdf:type schema:PropertyValue
182 N69097830af9646bdbf3f5a8e265a5ec2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Piperidines
184 rdf:type schema:DefinedTerm
185 N6c94e147e9a14c909478ae9dde75a0c3 schema:affiliation grid-institutes:grid.418424.f
186 schema:familyName Gerber
187 schema:givenName Sarah P.
188 rdf:type schema:Person
189 N6fa5fbb1ff434598bba4d99e591203d6 schema:affiliation grid-institutes:grid.418424.f
190 schema:familyName Teixeira
191 schema:givenName Sandra
192 rdf:type schema:Person
193 N7047b2e22e394c05ab6350bce4750b57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Animals
195 rdf:type schema:DefinedTerm
196 N70e12ae622604513bb22f3a3c1b6f709 rdf:first sg:person.01040067126.73
197 rdf:rest Ne67bb56d66f4462b9e9710ccf2ccfa90
198 N7d33e8d9b61d4bb980744584c83b4277 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Mice, Inbred C57BL
200 rdf:type schema:DefinedTerm
201 N82f3b2c6963f408bad7c1104f14c8a31 rdf:first sg:person.01150201134.05
202 rdf:rest N2ee444b4abaa4e11b7a02f7984a61f2e
203 N8732554db88d45d4852dd9325ec9a60b rdf:first sg:person.01011172531.53
204 rdf:rest N063f036eb6fb4f7cbcf6714be846133a
205 N89407d1f046c4ed8aaa59faffc37fb7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Brain
207 rdf:type schema:DefinedTerm
208 N8bbafa29c2144a4a9eb195243d99c6d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Sleep, REM
210 rdf:type schema:DefinedTerm
211 N8e7014f5d05e4dc5ad8aaede8d5a23d8 rdf:first N6fa5fbb1ff434598bba4d99e591203d6
212 rdf:rest rdf:nil
213 N967c57a3072c411ca69dee4d23029102 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Pyrimidinones
215 rdf:type schema:DefinedTerm
216 N9c55bfb2248b4d5d95ce4d6371cafa6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Rats
218 rdf:type schema:DefinedTerm
219 Na2ce251b4a424d50913c18835d5100ca schema:name Springer Nature - SN SciGraph project
220 rdf:type schema:Organization
221 Na705470780a04f73900b02d9cfb093cd rdf:first sg:person.01150042175.81
222 rdf:rest Ned2b792ed6a64543bd0e71893d19e8a7
223 Na7e4932a828f422491a02b1cb0b5c214 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
224 schema:name Receptor, Cannabinoid, CB1
225 rdf:type schema:DefinedTerm
226 Nb385d21b18ee481db7cfcd249c4d75e1 rdf:first sg:person.01034226026.36
227 rdf:rest N126c42cd209841489df2471273f92530
228 Nb8e7fe5242894e338585954f973b803e schema:name doi
229 schema:value 10.1007/s00210-011-0686-y
230 rdf:type schema:PropertyValue
231 Nbd9e45b790a74632b6542cd410915589 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
232 schema:name Obesity
233 rdf:type schema:DefinedTerm
234 Nc246610ca41e488ba149a37e01b2b1f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
235 schema:name Macaca fascicularis
236 rdf:type schema:DefinedTerm
237 Nc6bac8bdf178479e8350835b0384bb43 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
238 schema:name Drug Inverse Agonism
239 rdf:type schema:DefinedTerm
240 Nd0be0a18d7b44502b20e0bca67092203 rdf:first sg:person.01210642561.25
241 rdf:rest Nf247984d8cc3434a95e5749c274e6307
242 Nd12df7cdedb446579afe6c6559132090 rdf:first sg:person.015453371301.23
243 rdf:rest N30624a82136e479daeb693bdc4fddd43
244 Nd25f405aa38b462e85244999ed754f12 schema:volumeNumber 384
245 rdf:type schema:PublicationVolume
246 Nd8c824e90df941519572d4dfd6ca98a0 schema:issueNumber 6
247 rdf:type schema:PublicationIssue
248 Ne67bb56d66f4462b9e9710ccf2ccfa90 rdf:first sg:person.01164252563.05
249 rdf:rest N8e7014f5d05e4dc5ad8aaede8d5a23d8
250 Ne8892cb4659b49f9bea8eb7b3dab145e schema:name dimensions_id
251 schema:value pub.1001533608
252 rdf:type schema:PropertyValue
253 Ned2b792ed6a64543bd0e71893d19e8a7 rdf:first sg:person.01106253755.50
254 rdf:rest N70e12ae622604513bb22f3a3c1b6f709
255 Ned75cda1ccdb467e85b5bfc20a52e6ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
256 schema:name Pyrazoles
257 rdf:type schema:DefinedTerm
258 Nf18cc33b6bf148f8a2f849506cf55e80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
259 schema:name Motor Activity
260 rdf:type schema:DefinedTerm
261 Nf247984d8cc3434a95e5749c274e6307 rdf:first sg:person.01237227655.02
262 rdf:rest N324a13b7b35d4c2abe306b7b0aaaf86c
263 Nf9981d2d2b5145c5b1ef52f82cad2848 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
264 schema:name Rimonabant
265 rdf:type schema:DefinedTerm
266 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
267 schema:name Medical and Health Sciences
268 rdf:type schema:DefinedTerm
269 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
270 schema:name Neurosciences
271 rdf:type schema:DefinedTerm
272 sg:journal.1015404 schema:issn 0028-1298
273 1432-1912
274 schema:name Naunyn-Schmiedeberg's Archives of Pharmacology
275 schema:publisher Springer Nature
276 rdf:type schema:Periodical
277 sg:person.01011172531.53 schema:affiliation grid-institutes:grid.419481.1
278 schema:familyName Chaperon
279 schema:givenName Frederique
280 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01011172531.53
281 rdf:type schema:Person
282 sg:person.01034226026.36 schema:affiliation grid-institutes:grid.418185.1
283 schema:familyName Chen
284 schema:givenName Yu Alice
285 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034226026.36
286 rdf:type schema:Person
287 sg:person.01040067126.73 schema:affiliation grid-institutes:grid.419481.1
288 schema:familyName Jaton
289 schema:givenName Anne-Liese
290 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01040067126.73
291 rdf:type schema:Person
292 sg:person.01104030755.00 schema:affiliation grid-institutes:grid.418424.f
293 schema:familyName Dardik
294 schema:givenName Beatriz
295 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104030755.00
296 rdf:type schema:Person
297 sg:person.01106253755.50 schema:affiliation grid-institutes:grid.418185.1
298 schema:familyName Seidel
299 schema:givenName H. Martin
300 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106253755.50
301 rdf:type schema:Person
302 sg:person.01150042175.81 schema:affiliation grid-institutes:grid.418185.1
303 schema:familyName Liu
304 schema:givenName Hong
305 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150042175.81
306 rdf:type schema:Person
307 sg:person.01150201134.05 schema:affiliation grid-institutes:grid.418185.1
308 schema:familyName McNamara
309 schema:givenName Peter
310 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01150201134.05
311 rdf:type schema:Person
312 sg:person.01164252563.05 schema:affiliation grid-institutes:grid.418424.f
313 schema:familyName Gromada
314 schema:givenName Jesper
315 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164252563.05
316 rdf:type schema:Person
317 sg:person.01210642561.25 schema:affiliation grid-institutes:grid.419481.1
318 schema:familyName Jacobson
319 schema:givenName Laura H.
320 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210642561.25
321 rdf:type schema:Person
322 sg:person.01237227655.02 schema:affiliation grid-institutes:grid.418424.f
323 schema:familyName Commerford
324 schema:givenName S. Renee
325 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237227655.02
326 rdf:type schema:Person
327 sg:person.01347610057.60 schema:affiliation grid-institutes:grid.418185.1
328 schema:familyName Hollenbeck
329 schema:givenName Thomas
330 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347610057.60
331 rdf:type schema:Person
332 sg:person.015453371301.23 schema:affiliation grid-institutes:grid.418185.1
333 schema:familyName Nguyen-Tran
334 schema:givenName Van
335 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015453371301.23
336 rdf:type schema:Person
337 sg:person.0770431725.37 schema:affiliation grid-institutes:grid.418185.1
338 schema:familyName He
339 schema:givenName Xiaohui
340 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770431725.37
341 rdf:type schema:Person
342 sg:pub.10.1007/s00213-006-0650-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045515263
343 https://doi.org/10.1007/s00213-006-0650-6
344 rdf:type schema:CreativeWork
345 sg:pub.10.1038/346561a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034682253
346 https://doi.org/10.1038/346561a0
347 rdf:type schema:CreativeWork
348 sg:pub.10.1038/365061a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020160837
349 https://doi.org/10.1038/365061a0
350 rdf:type schema:CreativeWork
351 sg:pub.10.1038/ijo.2010.21 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018368508
352 https://doi.org/10.1038/ijo.2010.21
353 rdf:type schema:CreativeWork
354 sg:pub.10.1038/ijo.2010.38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053597823
355 https://doi.org/10.1038/ijo.2010.38
356 rdf:type schema:CreativeWork
357 sg:pub.10.1038/nature00839 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010507937
358 https://doi.org/10.1038/nature00839
359 rdf:type schema:CreativeWork
360 sg:pub.10.1038/nn.2494 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037682590
361 https://doi.org/10.1038/nn.2494
362 rdf:type schema:CreativeWork
363 sg:pub.10.1038/nrn2092 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012251851
364 https://doi.org/10.1038/nrn2092
365 rdf:type schema:CreativeWork
366 grid-institutes:grid.418185.1 schema:alternateName Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA
367 schema:name Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA
368 rdf:type schema:Organization
369 grid-institutes:grid.418424.f schema:alternateName Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA
370 schema:name Cardiovascular and Metabolism Disease Area, Novartis Institutes for BioMedical Research, Cambridge, MA, USA
371 rdf:type schema:Organization
372 grid-institutes:grid.419481.1 schema:alternateName Neuroscience Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland
373 schema:name Neuroscience Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland
374 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...